All Type of News
SK’s pneumococcal conjugate vaccine to be discussed at Central Pharmacists Deliberation Committee
The government will hold the Central Pharmacists Deliberation Committee over the conditional approval and clinical trials of the 13-valent pneumococcal conjugate vaccine that are being developed by SK Chemicals.
The...
Osong & Daegu Medical Innovation Foundations’ cooperation with largest European BioCluster
On the 5th, Osong Medical Innovation Foundation(Chief Director Kyung Sun) and Daegu Gyeongbuk Medical Innovation Foundation(Chief Director Jae-tae Lee) announced conclusion of the Strategic Exploratory Agreement(SEA) ...
Domestic pharmaceuticals conclude technology export contracts of KRW 9.3 trillion
It was observed the size of domestic pharmaceutical companies’ contracts for foreign technology exports exceeded KRW 9 trillion last year. Since the size does not include 8 of the total number of contracts, the total ...
Hyundai Pharm lost Yaz’s patent conflict against leading contraceptive company
Hyundai Pharm, a company owning the largest market share in the morning-after pill market, lost the patent conflict which attracted attention of the industry since it was against the leading company in birth control p...
Demo project for hospitalists starts in 32 medical institutes this July
Although the demo project to adopt inpatient professionals, also known as hospitalists, will start this July, patients will actually be able to take the service in the 2nd half of the year when each medical institute ...
Brilinta’s patent nullification competition fueled even more among pharmaceutical companies
While domestic pharmaceutical companies are competing over the patent nullification of the AstraZeneca’s antithrombotic, ‘Brilinta,’ the recent establishment of many claims for the patent is expected to solidify the c...
Amgen Korea, “We will focus on successful launches of products returned”Amgen Korea announced plans to focus on the domestic settlement of 3 products acquired from GSK.
The company shared future goals and plans to enter the Korean market on Februar...
|
KPDS, “The MFDS’s measure on olmesartan is inadequate”
The prescription policy for olmesartan, a hypertensive treatment, has been re-discussed.
On the 2nd, the Korean Pharmacists for Democratic Society(hereinafter referring to KPDS) emphasized necessity to tighten the p...
‘Swift Evaluation’ on new drugs approved for the first time in Korea
The government will push forward with a measure for newly-approved new drugs for the first time in Korea to pass insurance benefit propriety evaluations within 100 days in Korea. It has decided to introduce the so-cal...
Hanmi and Hanlim to win patent suit against Cipla, protecting their complexes
Hanmi Pharm and Hanlim Pharm won a patent suit against an Indian generic company, ‘Cipla.’
Conclusion of the suit has urgently attracted the industry since it was related to Hanmi Pharm and Hanmil Pharm’s self-develo...
